Interní Med. 2016; 18(3): 125-129 | DOI: 10.36290/int.2016.036

Antidiabetic drugs of interest

prof.MUDr.Milan Kvapil, CSc.
Interní klinika, FN Motol, Praha

The increasing prevalence of type 2 diabetes mellitus is a major epidemiological, clinical, and economic issue. Good-quality treatment

aimed at achieving normal blood sugar levels is essential in order to prevent complications. Novel molecules (dapagliflozin,

empagliflozin, imeglimin, liraglutide, omarigliptin, ranolazine, and sitagliptin) that have been introduced in the clinical practice

in the recent years, or are going to be introduced, show a lower risk of hypoglycaemia, thus allowing superior prevention of late

complications of type 2 diabetes.

Keywords: type 2 diabetes mellitus, dapagliflozin, empagliflozin, imeglimin, liraglutide, omarigliptin, ranolazine, sitagliptin

Published: July 1, 2016  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kvapil M. Antidiabetic drugs of interest. Interní Med. 2016;18(3):125-129. doi: 10.36290/int.2016.036.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Broz J, Kvapil M. Sitagliptin pro rok 2016. In Kvapil M (eds) Diabetologie 2016. Triton, Praha 2016.
    2. Green JB, Bethel MA, Paul SK, Ring A, Kaufman KD, Shapiro DR, Califf RM, Holman RR. Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease. Am Heart J. 2013; 166(6): 983-989.e7. Go to original source... Go to PubMed...
    3. Du Q, Wu B, Wang YJ, Yang S, Zhao YY, Liang YY. Comparative effects of sitagliptin and metformin in patients with type 2 diabetes mellitus: a meta-analysis. Curr Med Res Opin. 2013; 29(11): 1487-1494. Go to original source... Go to PubMed...
    4. Zhan M, Xu T, Wu F, Tang Y. Sitagliptin in the treatment of type 2 diabetes: a meta-analysis. J Evid Based Med. 2012; 5(3): 154-165. Go to original source...
    5. Goldstein BJ, Feinglos MN, Lunceford JK, Johnson J, Williams-Herman DE; Sitagliptin 036 Study Group. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care. 2007; 30(8): 1979-1987. Go to original source...
    6. Engel SS, Golm GT, et al. Cardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysis. Cardiovasc Diabetol. 2013; 12: 3. Go to original source... Go to PubMed...
    7. Scirica BM, et al. the SAVOR-TIMI 53 Steering Committee and Investigators: Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus. N Engl J Med 2013; 369(14): 1317-1326. Go to original source...
    8. Pátek O, Kvapil M. TECOS. In Kvapil M (eds) Diabetologie 2016. Triton, Praha 2016.
    9. Kvapil M. Sitagliptin rok po studii TECOS: lék první volby s metforminem? In Kvapil M. ed: Diabetologie 2016, Triton, Praha 2016.
    10. Kvapil M. Sitagliptin pro rok 2012. In Kvapil M (eds) Diabetologie 2012. Triton, Praha 2012.
    11. Kvapil M. Postavení fixní kombinace antidiabetik v terapii. Remedia, 2013; 23(4): 2-5.
    12. Kvapil M. Dapagliflozin: klinické aspekty použití. Farmakoterapie 2014; 10(1): 83-87.
    13. Sonesson C, et al. Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis. Cardiovasc Diabetol. 2016; 15(1): 37. Go to original source... Go to PubMed...
    14. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE; EMPA-REG OUTCOME Investigators. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015; 373(22): 2117-2128. Go to original source...
    15. Kvapil M. EMPA REG OUTCOME Důkaz, že populace pacientů s diabetem se mění. Remedia 2016; 26: 67-72.
    16. Nichols GA, Koro CE, Gullion CM, Ephross SA, Brown JB. The incidence of congestive heart failure associated with antidiabetic therapies. Diabetes Metab Res Rev. 2005; 21(1): 51-57. Go to original source...
    17. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071627.pdf
    18. Kvapil M. Liraglutid. Farmakoterapie 2010; 6(1): 21-27.
    19. Marso SP, et al. Design of the liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER) trial. Am Heart J. 2013; 166(5): 823-830. Go to original source...
    20. Gough SC, Bode B, Woo V, Rodbard HW, Linjawi S, Poulsen P, Damgaard LH, Buse JB; NN9068-3697 (DUAL-I) trial investigators. Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes. Lancet Diabetes Endocrinol. 2014; 2(11): 885-893. Go to original source... Go to PubMed...
    21. Buse JB, Vilsb?ll T, Thurman J, Blevins TC, Langbakke IH, B?ttcher SG, Rodbard HW; NN9068-3912 (DUAL-II) Trial Investigators. Contribution of liraglutide in the fixed-ratio combination of insulin degludec and liraglutide (IDegLira). Diabetes Care. 2014; 37(11): 2926-2933. Go to original source...
    22. Gantz, I. et al. Effect of MK-3102, a novel once-weekly DPP-4 inhibitor, over 12-weeks in patiens with type 2 diabeetes mellitus. Diabetologia 2012; 55(Suppl 1): S 51.
    23. Sheu WH, et al. Safety and Efficacy of Omarigliptin (MK-3102), a Novel Once-Weekly DPP-4 Inhibitor for the Treatment of Patients With Type 2 Diabetes. Diabetes Care. 2015; 38(11): 2106-2114. Go to original source...
    24. http://clinicaltrials.gov/ct2/results?term=MK-3102&Search=Search.
    25. Addy C, et al. Pharmacokinetic and Pharmacodynamic Effects of Multiple-Dose Administration of Omarigliptin, a Once-Weekly Dipeptidyl Peptidase-4 Inhibitor, in Obese Participants With and Without Type 2 Diabetes Mellitus. Clin Ther. 2016 Feb 8. pii: S0149-2918(16)00016-3. Go to original source... Go to PubMed...
    26. Vial G, Chauvin MA, Bendridi N, Durand A, Meugnier E, Madec AM, Bernoud-Hubac N, Pais de Barros JP, Fontaine É, Acquaviva C, Hallakou-Bozec S, Bolze S, Vidal H, Rieusset J. Imeglimin normalizes glucose tolerance and insulin sensitivity and improves mitochondrial function in liver of a high-fat, high-sucrose diet mice model. Diabetes. 2015; 64(6): 2254-2264. Go to original source... Go to PubMed...
    27. Pacini G, Mari A, Fouqueray P, Bolze S, Roden M. Imeglimin increases glucose-dependent insulin secretion and improves ?-cell function in patients with type 2 diabetes. Diabetes Obes Metab. 2015; 17(6): 541-545. Go to original source...
    28. Fouqueray P, et al. Dose - rating study to determine the optimum dose for imeglimin a novel treatment for type 2 diabetes. Diabeetes 2015; 64: Suppl 1; 1169P.
    29. Fouqueray P, Pirags V, Inzucchi SE, Bailey CJ, Schernthaner G, Diamant M, Lebovitz HE. The efficacy and safety of imeglimin as add-on therapy in patiens with type 2 diabetes inadequately controlled with metformin monotherapy. Diabetes Care. 2013; 36(3): 565-568. Go to original source...
    30. Fouqueray P, Pirags V, Diamant M, Schernthaner G, Lebovitz HE, Inzucchi SE, Bailey CJ. The efficacy and safety of imeglimin as add-on therapy in patiens with type 2 diabetes inadequately controlled with sitagliptin monotherapy. Diabetes Care. 2014; 37(7): 1924-1930. Go to original source...
    31. Pacini G, Mari A, Fouqueray P, Bolze S, Roden M. Imeglimin increases glucose-dependent insulin secretion and improves ?-cell function in patients with type 2 diabetes. Diabetes Obes Metab. 2015; 17(6): 541-545. Go to original source...
    32. Pirags V, Lebovitz H, Fouqueray P. Imeglimin, a novel glimin oral antidiabetic, exhibits a good efficacy and safety profile in type 2 diabetic patients. Diabetes Obes Metab. 2012; 14(9): 852-858. Go to original source...
    33. Vuylsteke V, Chastain LM, Maggu GA, Brown C. Imeglimin: A Potential New Multi-Target Drug for Type 2 Diabetes. Drugs R D. 2015; 15(3): 227-232. Go to original source...
    34. Kvapil M. Imeglimin. In Kvapil ed: Diabetologie 2016, Triton, Praha, 2016, in press.
    35. Arnold SV, et al. Effectiveness of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina according to baseline hemoglobin A1c. Am Heart J. 2014; 168(4): 457-465. Go to original source...
    36. Kosiborod M, et al. Evaluation of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina: results from the TERISA randomized clinical trial (Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina). J Am Coll Cardiol. 2013; 61(20): 2038-2045. Go to original source...
    37. Chisholm JW, et al. Effect of ranolazine on A1C and glukose levels in hyperglycemic patients with non-ST elevation acute coronary syndrome. Diabetes Care. 2010; 33(6): 1163-1168. Go to original source... Go to PubMed...
    38. Marso SP, Poulter NR, Nissen SE, Nauck MA, Zinman B, Daniels GH, Pocock S, Steinberg WM, Bergenstal RM, Mann JF, Ravn LS, Frandsen KB, Moses AC, Buse JB. Design of the liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER) trial. Am Heart J. 2013; 166(5): 823-830. Go to original source...
    39. Hampp C, Borders-Hemphill V, Moeny DG, Wysowski DK. Use of antidiabetic drugs in the U.S., 2003-2012. Diabetes Care. 2014; 37(5): 1367-1374. Go to original source...
    40. Scott DA, Boye KS, Timlin L, Clark JF, Best JH. A network meta-analysis to compare glycaemic control in patients with type 2 diabetes treated with exenatide once weekly or liraglutide once daily in comparison with insulin glargine, exenatide twice daily or placebo. Diabetes Obes Metab. 2013; 15(3): 213-223. Go to original source...
    41. Kvapil M. EMPA REG OUTCOM: důkaz, že populace pacientů s diabetem se mění Remedia 2016; 26(1): 67-72.
    42. https://clinicaltrials.gov/ct2/show/NCT01730534?term=dapagliflozin+AND+DECLARE&rank=1.

    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.